Taxol-based eluting stents - From theory to human validation: Clinical and intravascular ultrasound observations

Journal of Invasive Cardiology

Volumn 15, Issue 3, 2003, Pages 109-114

  Sonoda, Shinjo ^a   Honda, Yasuhiro ^a   Kataoka, Toru ^a   Bonneau, Heidi N ^b   Sudhir, Krishnankutty ^a   Yock, Paul G ^a   Mintz, Gary S ^c   Fitzgerald, Peter J ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Highlands Consulting Inc   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug eluting stents; Intravascular ultrasound; Paclitaxel

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; PACLITAXEL; PACLITAXEL DERIVATIVE; POLYMER; QP 2; RAPAMYCIN;

ANGIOGRAPHY; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL REACTIVITY; BRADYCARDIA; BRONCHOSPASM; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; ELUTION; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY; HYPOTENSION; IMPLANTATION; INTRAVASCULAR ULTRASOUND; LIPOPHILICITY; MACROPHAGE; MATERIAL COATING; MICROTUBULE; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; RESTENOSIS; SIDE EFFECT; SMOOTH MUSCLE FIBER; STENT; THEORY; URTICARIA; VALIDATION PROCESS; VASCULAR SMOOTH MUSCLE;

ANGIOGENESIS INHIBITORS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CARDIAC SURGICAL PROCEDURES; CLINICAL TRIALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; HUMANS; PACLITAXEL; REPRODUCIBILITY OF RESULTS; STENTS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0037341286     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. The BENESTENT Study Group. N Engl J Med 1994;331:489-495.
3. Erbel R, Haude M, Hopp HW, et al. Coronary artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998;339:1672-1678.
4. Edelman ER, Rogers C. Hoop dreams. Stents without restenosis. Circulation 1996;94:1199-1202.
5. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-1254.
6. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-1703.
7. Teirstein PS, Massullo V, Jani S, et al. Three-year clinical and angiographic follow-up after intracoronary radiation: Results of a randomized clinical trial. Circulation 2000;101:360-365.
8. Albiero R, Adamian M, Kobayashi N, et al. Short- and intermediateterm results of (32)P radioactive beta-emitting stent implantation in patients with coronary artery disease: The Milan Dose-Response Study. Circulation 2000;101:18-26.
9. Albiero R, Nishida T, Adamian M, et al. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation 2000;101:2454-2457.
10. Costa MA, Sabat M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999;100:789-792.
11. Heldman AW, Cheng L, Heller PF, et al. Paclitaxel applied directly to stents inhibits neointimal growth without thrombotic complications in a porcine coronary artery model of restenosis. Circulation 1997;96:1288.
12. Brieger D, Topol E. Local drug delivery systems and prevention of restenosis. Cardiovasc Res 1997;35:405-413.
13. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327.
14. Schiff PB, Fant J, Horwitz SB, Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-667.
15. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-1259.
16. Rowinsky EK, Donehower RC. Paclitaxel (taxol), published erratum appears in N Engl J Med 1995;333:75. N Engl J Med 1995;332:1004-1014.
17. Donaldson KL, Goolsby GL, Kiener PA, Wahl AF. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 1994;5:1041-1050.
18. Straubinger RM, Sharma A, Murray M, Mayhew E. Novel taxol formations: Taxol-containing liposomes. J Natl Cancer Inst Monogr 1993;15:69-78.
19. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993;90:9552-9556.
20. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-1876.
21. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery (see comments). Circulation 1997;96:636-645.
22. Hou D, Rogers PI, Toleikis PM, et al. Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch. Circulation 2000;102:1575-1581.
23. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: Biological effects and efficacy in vivo. J Am Coll Cardiol 2000;35:1969-1976.
24. Oberhoff M, Herdeg C, Al Ghobainy R, et al. Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Cathet Cardiovasc Interv 2001;53:562-568.
25. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-2332.
26. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-2295.
27. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479.
28. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern govem drug distribution for stent-based delivery. Circulation 2001;104:600-605.
29. de la Fuente LM, Miano J, Mrad J, et al. Initial results of the Quanam drug-eluting stent (QuaDS-QP-2) registry (BARDDS) in human subjects. Cathet Cardiovasc Interv 2001;53:480-488.
30. Honda Y, Grube E, de la Fuente ML, et al. Novel drug-delivery stent: Intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001;104:380-383.
31. Grube E, Lansky AJ, Reifart N, et al. SCORE six-month angiographic results: Improved restenosis in patients receiving the QuaDDS-QP2 drug-eluting stent compared with the control, bare stents. J Am Coll Cardiol 2002;39(Suppl A):59A.
32. Park SJ, Shim WH, Ho DS, et al. The clinical effectiveness of paclitaxel-coated coronary stents for the reduction of restenosis in the ASPECT trial. Circulation 2001;104(Suppl II):II-464.
33. Gershlick AH, De Scheerder I, Chevalier B, et al. Local drug delivery to inhibit coronary artery restenosis: Data from the ELUTES (Evaluation of Paclitaxel Eluting Stent) clinical trial. Circulation 2001;104(Suppl II):II-416.
34. Grube E, Silber SM, Hauptmann KE. Taxus I: Prospective, randomized, double-blind comparison of NIRx stents coated with paclitaxel in a polymer carrier in de novo coronary lesions compared with uncoated controls. Circulation 2001;104(Suppl II):II-463.
35. Kataoka T, Grube E, Honda Y, et al. 7-Hexanolytaxol-eluting stent for prevention of neointimal growth: An intravascular ultrasound analysis from the SCORE trial. Circulation 2002;106:1788-1793.
36. Kataoka T, Grube E, Hur SH, et al. Intravascular ultrasound stent edge analysis following drug-eluting stent implantation: "Candy without the wrapper". Circulation 2001;104(Suppl II):II-770.
37. Hong MK, Mintz GS, Park SW, et al. Paclitaxel coating reduces in-stent restenosis: A serial volumetric intravascular ultrasound analysis. J Am Coll Cardiol 2002;39(Suppl A):38A.
38. Mintz GS, Hong MK, Weissman NJ, et al. Lack of edge effects, late malapposition, or black holes after paclitaxel-coated stent implantation: An intravascular ultrasound study. Am J Cardiol 2002;90(Suppl 6A):2H.
39. Grube E, Hauptmann K, Colombo A, et al. SCORE trial interim safety results: Despite efficacy, late stent thrombosis with the QuaDDS-QP2 stent. J Am Coll Cardiol 2002;39(Suppl A):38A.
40. Sousa JE, Costa MA, Abizaid AC, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.
41. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-2011.
42. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
43. Ako J, Morino Y, Sonoda S, et al. Effect of sirolimus-eluting stents on neointimal hyperplasia: A serial in-stent intravascular ultrasound interim analysis from the SIRIUS trial. Am J Cardiol 2002;90(Suppl 6A):2H.
44. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation 2002;106:798-803.